COMPASS Pathways (CMPS) Stock Forecast & Price Target

Compass Pathways is well positioned because COMP360 has produced strong, reproducible clinical evidence in treatment-resistant depression, including a 39% clinically meaningful response in the 25 mg arm of COMP006 with benefits maintained through 26 weeks and a clean safety profile. The company is also transitioning into commercialization, with a rolling NDA partially submitted, FDA review underway, all remaining modules targeted for 4Q26, and a potential 1H27 launch supported by a favorable expected label, DEA rescheduling progress, and more than 8,000 potential clinic sites. Financially, Compass ended the quarter with $433.3 million of cash and runway into 2028, while the PTSD program and VA-backed PIVOT study add underappreciated longer-term upside beyond the core TRD opportunity.

Compass Pathways is exposed to substantial clinical and regulatory uncertainty, since COMP-360 and other pipeline programs could fail in trials, encounter safety setbacks, or never secure FDA approval. As a biotechnology company with a single operating segment, it also faces material commercial headwinds from competition and insurer pressure, which could limit uptake even if development progresses. The risk of a dilutive equity offering further weakens the investment case by threatening shareholder dilution while the company still depends on successful clinical outcomes and regulatory milestones.